Curis Announces Three Abstracts for CA-4948 Accepted for Presentation at the 62nd American Society of Hematology Annual Meeting and ExpositionPRNewsWire • 11/04/20
Curis Highlights Publication in ACS Medicinal Chemistry Letters Showcasing Targeted Potency and Ideal Pharmacologic Properties of CA-4948 for Treatment of Hematologic MalignanciesPRNewsWire • 10/21/20
Curis Announces Abstract for CI-8993 Accepted for Presentation at the Society for Immunotherapy of Cancer's (SITC) 35th Anniversary Annual MeetingPRNewsWire • 10/14/20
Curis, Inc. (CRIS) CEO Jim Dentzer on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/05/20
Curis, Inc. (CRIS) CEO Jim Dentzer on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/13/20
Curis Inc.'s (CRIS) CEO James Dentzer on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 03/19/20
Curis Inc.'s (CRIS) CEO James Dentzer on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/05/19
Curis, Inc. (CRIS) CEO Jim Dentzer on Q1 2019 Results - Earnings Call TranscriptSeeking Alpha • 05/14/19
Curis, Inc. (CRIS) CEO Jim Dentzer on Q4 2018 Results - Earnings Call TranscriptSeeking Alpha • 03/26/19
Curis' stock rockets on heavy volume after $135.7 million deal to sell portion of Erivedge royaltiesMarket Watch • 03/25/19